The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Noninferiority of S-1 to UFT/LV as adjuvant chemotherapy for stage III colon cancer: A randomized phase III trial (ACTS-CC).
Yoshihiko Nakamoto
No relevant relationships to disclose
Megumi Ishiguro
Consultant or Advisory Role - Bristol-Myers Squibb; Merck Serono; Taiho Pharmaceutical
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Yakult Honsha
Motoki Yoshida
Honoraria - Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical; Takeda
Koji Ikejiri
Research Funding - Taiho Pharmaceutical
Izumi Mochizuki
No relevant relationships to disclose
Hidetaka Mochizuki
Honoraria - Otsuka; Taiho Pharmaceutical
Research Funding - Otsuka; Pfizer; Taiho Pharmaceutical; Takeda
Kenjiro Kotake
Honoraria - Taiho Pharmaceutical; Takeda
Shingo Kameoka
Honoraria - Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical; Takeda
Keiichi Takahashi
Honoraria - Taiho Pharmaceutical; Takeda
Toshiaki Watanabe
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Masahiko Watanabe
No relevant relationships to disclose
Narikazu Boku
Honoraria - Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical
Naohiro Tomita
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
Yoshihiro Matsubara
No relevant relationships to disclose
Kenichi Sugihara
Consultant or Advisory Role - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kaken Pharmaceutical; Kyowa Hakko Kirin; Merck Serono; Ono Pharmaceutical ; Otsuka; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Wyeth; Yakult Honsha